Array Biopharma’s asthma drug helps lung function in study – Denver Post

Array Biopharma's asthma drug helps lung function in study
Denver Post
Boulder-based Array Biopharma Inc. said one of its drugs met the main goal of improving lung function in a mid-stage study among patients with mild to moderate persistent allergic asthma. Array shares rose 10.4 percent Tuesday, to close at $6.14 after 
Array Seeks Asthma Drug Partner Following Mid-Stage Study ResultsTheStreet.com
Array Shares Climb After Asthma Drug Shows Positive Phase 2 ResultsXconomy
Array BioPharma: ARRY-502 Meets Primary And Secondary Endpoints In NASDAQ
FierceBiotech –The Pharma Letter
all 15 news articles »

View full post on asthma – Google News

Array Biopharma’s new asthma drug meets goal of improved lung function – Denver Post

Array Biopharma's new asthma drug meets goal of improved lung function
Denver Post
Array Biopharma Inc. said Tuesday, one of its drugs met the main goal of improving lung function in a mid-stage study among patients with mild to moderate persistent allergic asthma. Array shares rose 12.7 percent, or 71 cents, to $6.27 in morning
Array BioPharma: Study Shows Asthma Candidate ARRY-502 Improves Lung Wall Street Journal
Array BioPharma scores midstage success for asthma drugFierceBiotech
Array Shares Climb After Asthma Drug Shows Positive Phase 2 ResultsXconomy
NASDAQ –TheStreet.com –KFGO
all 10 news articles »

View full post on asthma – Google News